26-06-2020
The executive director of the Medicines Patent Pool (MPP) says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
MPP, LSPN Connect, Medicines Patent Pool, voluntary licensing, COVID-19, pandemic, Charles Gore, Big Pharma, drug companies, HIV, hepatitis C, WHO, UN
LSPN Connect: micro-managing with Pendulum Therapeutics
06-08-2020
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31-07-2020
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
23-07-2020
LSPN Connect: When IP and COVID-19 meet
10-07-2020
WHO and Costa Rica to launch COVID-19 technology patent pool
19-05-2020
Costa Rica asks WHO to create voluntary COVID-19 IP pool
26-03-2020
